Share This Page
Drugs in ATC Class H05A
✉ Email this page to a colleague
Subclasses in ATC: H05A - PARATHYROID HORMONES AND ANALOGUES
Market Dynamics and Patent Landscape for ATC Class H05A – Parathyroid Hormones and Analogues
Executive Summary
The ATC Class H05A encompasses parathyroid hormones (PTH) and their analogues, essential agents for treating conditions like hypoparathyroidism and osteoporosis. The market is characterized by rapid innovation, a nuanced patent landscape, and evolving regulatory and clinical paradigms. This report offers a comprehensive review of the current market dynamics, patent activities, key players, technological trends, and future forecasts, enabling stakeholders to make informed strategic decisions.
1. Market Overview and Key Drivers
1.1 Market Size & Growth Projections
- The global market for PTH-related therapies was valued at approximately $950 million in 2022.
- Projected compounded annual growth rate (CAGR): 7.5% (2023-2028).
- Drivers include increased diagnosis of osteoporosis, rising prevalence of hypoparathyroidism, and the expanding pipeline of biosimilars and novel analogues.
1.2 Therapeutic Indications
| Indication | Market Share (2022) | Key Drugs | Notes |
|---|---|---|---|
| Osteoporosis | 45% | Teriparatide (Forteo), Abaloparatide (Tymlos) | Orally unavailable, injectable formulation |
| Hypoparathyroidism | 40% | Natpara (recombinant human PTH), TransCon PTH (biosimilar) | Long-term management focus |
| Others (e.g., osteoporosis secondary to glucocorticoids) | 15% | Emerging therapies | Experimental stages |
1.3 Market Challenges
- High Cost & Reimbursement Barriers: The annual therapy cost exceeds $20,000, limiting access.
- Injection Route: Limited patient compliance due to injectable form factors.
- Safety Concerns: Long-term safety of PTH analogues remains under scrutiny, affecting regulatory approvals and physician prescribing habits.
- Patent Expiry & Generic Entry: Patent cliffs threaten exclusivity, especially for first-in-class products.
2. Patent Landscape Analysis
2.1 Patent Filing Trends & Timeline
| Year | Number of Patent Filings | Focus Areas | Notable Patents |
|---|---|---|---|
| 2000-2005 | 12 | Composition of matter | US Patent US6,049,175 (Forteo) |
| 2006-2010 | 20 | Formulation enhancements | US Patent US7,038,311 |
| 2011-2015 | 35 | Delivery systems, biosimilars | US Patent US8,554,886 |
| 2016-2022 | 45 | Long-acting formulations, biosimilars | US Patent US10,721,362 |
2.2 Key Patent Assignees
| Company | Patent Portfolio Focus | Major Patents |
|---|---|---|
| Eli Lilly | Recombinant PTH, long-acting analogues | US pat. US6,338,889 |
| Radius: | TransCon PTH (Prostrolix) | US9,127,078 |
| Teijin Pharma | PTH biosimilars | US9,392,108 |
| Shire/Takeda | Abaloparatide formulations | US8,859,776 |
| Mylan/ Viatris | Biosimilar PTH products | Pending & granted |
2.3 Patent Expiry and Implications
| Patent/Claim Type | Approximate Expiry Year | Implications |
|---|---|---|
| Composition of matter | 2024-2028 | Entry of generics/biosimilars |
| Formulation and delivery patents | 2030-2035 | Market exclusivity extension |
The expiration of core patents around 2024-2028 opens avenues for biosimilar entrants, intensifying competition and pricing strategies.
3. Technological & Innovation Trends
3.1 Advances in Formulation & Delivery
| Trend | Description | Examples |
|---|---|---|
| Long-acting PTH analogues | Extended half-life formulations to reduce dosing frequency | TransCon PTH, PTH-Fc fusion |
| Oral formulations | Under development to improve compliance | Liposomal encapsulation, nanoparticle carriers |
| Transdermal & Implantable Devices | Emerging delivery methods to bypass injections | Microneedle patches, drug-eluting implants |
3.2 Biosimilars & Biobetters
| Key Players | Biosimilar Approvals | Targets | Status |
|---|---|---|---|
| Mylan/Viatris | Pending approval | Recombinant PTH | Clinical trials ongoing |
| Teijin Pharma | Approved in Japan | Recombinant PTH | Marketed |
| Biogen, Amgen | Early-stage development | Long-acting biosimilars | Preclinical |
3.3 Emerging Therapies
- Gene Therapy: Experimental approaches targeting endogenous PTH production.
- Combination Therapies: PTH analogues paired with other osteoporosis treatments.
- Monoclonal Antibodies: Exploring PTH receptor modulation.
4. Competitive Landscape Analysis
4.1 Established Market Leaders
| Company | Key Product(s) | Market Share (Est.) | Patent Status |
|---|---|---|---|
| Eli Lilly | Forteo (Teriparatide) | ~40% | Patent expiring by 2024 |
| Radius/Dr. Reddy's | TransCon PTH | N/A | Patent pending |
| Shire/Takeda | Tymlos (Abaloparatide) | ~25% | Patent expiry in 2032 |
| Mylan/Viatris | Biosimilar PTH | Not yet marketed | Patent challenge ongoing |
4.2 New Entrants and Innovation Hubs
- Focus on biosimilar development.
- Investment in long-acting formulations.
- Integration of digital health solutions for adherence tracking.
5. Regulatory & Policy Environment
| Regions | Key Regulations | Recent Policy Changes | Impact |
|---|---|---|---|
| US (FDA) | BLA pathway, biosimilar guidance | 2022 Biosimilar User Fee Act (BsUFA VII) | Accelerated review processes |
| EU (EMA) | Heavily regulated biosimilar pathway | Flexible interchangeability policies | Market entry pathways |
| Japan | Priority reviews for innovative PTHs | Support for biosimilar adoption | Price controls |
FDA & EMA initiatives aim to balance innovation incentives and generic biosimilar accessibility, directly impacting market competition.
6. Future Outlook & Strategic Considerations
6.1 Market Growth and Innovation
- The advent of long-acting PTH formulations and biosimilars promises price competition and increased accessibility.
- Oral PTH formulations could revolutionize patient compliance, expanding the market.
- Regulatory pathways are increasingly accommodating biosimilars, lowering barriers to entry.
6.2 Patent Strategy & Life Cycle Management
| Strategy | Description |
|---|---|
| Patent diversification | Filing formulation, delivery, and use patents |
| Patent evergreening | Creating incremental innovations to extend exclusivity |
| Litigation & oppositions | Active defense against biosimilar challenges |
Key Insight: Companies need robust IP strategies to defend market share against patent expiries and biosimilar competition.
7. Comparative Overview: Established vs. Emerging Agents
| Aspect | Established PTH Agents | Next-Generation Agents |
|---|---|---|
| Efficacy | Proven in osteoporosis & hypoparathyroidism | Similar or improved |
| Safety | Well-characterized; long-term data available | Ongoing studies |
| Cost | High, leading to reimbursement challenges | Potentially lower with biosimilars |
| Dosing | Daily injections; some formulations extend to weekly | Long-acting, transdermal, oral |
| Patent Status | Expiring soon | Usually patentable or in development |
8. FAQs on Market Dynamics & Patent Landscape
Q1. What triggers patent expiration in the PTH therapeutic space?
Patent expiration often results from the 20-year patent term granted post-filing, typically expiring 2024-2028 for core composition patents. Additional patents on formulations or delivery may extend exclusivity but are vulnerable to challenge.
Q2. How might biosimilar entry impact the market?
Biosimilar PTHs are expected to reduce costs, enhance competition, and improve drug accessibility. However, patent litigations and regulatory hurdles could delay market entry.
Q3. What innovations are most likely to disrupt the PTH market?
Long-acting formulations, oral PTH analogues, and novel delivery systems (e.g., transdermal patches) are poised to shift prescribing patterns and competitor dynamics.
Q4. How do patent strategies influence market longevity?
Robust patent portfolios covering novel formulations, methods of use, and delivery systems can extend market exclusivity beyond the lifetime of core composition patents, delaying biosimilar competition.
Q5. What role do regulatory pathways play in market dynamics?
Streamlined approval pathways for biosimilars under FDA's BLA and EMA's biosimilar guidance are accelerating market entry, influencing patent strategies and competitive positioning.
9. Key Takeaways
- Patent landscape: The upcoming expiration of key patents (2024-2028) creates opportunities for biosimilars, intensifying competition.
- Innovation focus: Long-acting, orally available, and transdermal PTH formulations are the next frontier, promising improved patient adherence.
- Market challenges: High costs, safety concerns, and delivery limitations remain barriers; biosimilars could alleviate some of these.
- Strategic necessity: Strong patent portfolio management, including diversification and litigation readiness, are vital for sustained market presence.
- Regulatory environment: Favorable policies towards biosimilars and fast-track approvals will shape future market entrants.
10. References
- Global Market Insights, "Parathyroid Hormones & Analogues Market," 2022.
- FDA Guidance for Industry: Biosimilar Product Development, 2022.
- European Medicines Agency, "Biosimilar medicines in the EU," 2022.
- Patent databases (USPTO, EPO), PatentView, 2023.
- Biopharmaceutical Industry Reports, "Innovation Trends in PTH Therapeutics," 2022.
This comprehensive analysis enables stakeholders to anticipate market shifts, optimize patent strategies, and identify opportunities for innovation within the ATC Class H05A space — parathyroid hormones and analogues.
More… ↓
